TCRX on XNAS, Health Care, TScan Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Delisting notice filed as the stock fell 85% in a year and revenue dropped 38%.
BadLayoff notices for 96 workers, up from none the year before
BadNet loss of $115.1M over 12 months, with cash outflow of $111.7M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $586K, net loss $33.1M.
31 Dec 2021RevenueNet incomeNet losstallest bar $37.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$586K
-$33.1M
30 Jun 2026
$1.1M
-$30.4M
31 Mar 2026
$982K
-$28.7M
31 Dec 2025
$2.6M
-$23.0M
30 Sep 2025
$2.5M
-$35.7M
30 Jun 2025
$3.1M
-$37.0M
31 Mar 2025
$2.2M
-$34.1M
31 Dec 2024
$665K
-$35.8M
30 Sep 2024
$1.0M
-$29.9M
30 Jun 2024
$536K
-$31.7M
31 Mar 2024
$566K
-$30.1M
31 Dec 2023
$7.2M
-$19.6M
30 Sep 2023
$3.9M
-$23.0M
30 Jun 2023
$3.1M
-$24.0M
31 Mar 2023
$6.8M
-$22.6M
31 Dec 2022
$3.1M
-$18.7M
30 Sep 2022
$3.4M
-$16.2M
30 Jun 2022
$4.1M
-$15.1M
31 Mar 2022
$3.0M
-$16.2M
31 Dec 2021
$2.9M
-$14.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$5.2M
$8.4M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-38%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$115.1M
-$142.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-126%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$111.7M
-$135.9M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$73.0M
$184.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$33.0M
$32.4M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$40.1M (net cash)
-$152.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.87
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.9
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.26
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-97%
$41K vs $1.4M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-12%
52 13F filers vs 59
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
2.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.7
2.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-11%
2.3M shares sold short in the report before, 2.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
39%
39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 36%
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
96
the 12 months before: 0
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
6 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
Layoff notice 96 workers
Price $0.15 on 20 Nov 2026, -85% over 12 months (12-month range $0.14 to $1.43)
Sharp change
8-K and other filings
WARN layoff notice
Insider net buying (open market). Insiders bought a net $146K in the last 12 months (the 12 months before: $3.5M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 7 published in the last 12 months, -12% on the 12 months before.Revenue per quarter. Revenue $586K in the latest quarter, -77% on a year earlier.Capital spending per quarter. Capital spending $41K in the latest quarter, -97% on a year earlier.Institutional holders (13F filers). 52 13F filers reported holding it in the latest 13F quarter, -29% on a year earlier.Workers in WARN layoff notices. Workers in WARN layoff notices: 96 published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend.
In 12 months: 6 director or officer changes, 1 agreement ended, 1 restructuring, 1 delisting notice. Results releases and routine reports are left out.
Two or more unrelated kinds of records unusual within 30 days
20 Aug 2024confirmed
Confirmed across sources Institutional holdings and Short interest and volume
TScan Therapeutics(TCRX): saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year, while it had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year. Two unrelated kinds of activity within 168 days.
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
Short interest and volume: Short interest spike, became public on 27 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
Short interest and volume: Short interest spike, became public on 25 Sep 2024
Short interest and volume: Short interest spike, became public on 10 Oct 2024
Short interest and volume: Short interest spike, became public on 25 Oct 2024
Short interest and volume: Short interest spike, became public on 13 Nov 2024
Short interest and volume: Short interest spike, became public on 27 Nov 2024
Short interest and volume: Short interest spike, became public on 11 Dec 2024
Short interest and volume: Short interest spike, became public on 25 Dec 2024
Short interest and volume: Short interest spike, became public on 14 Jan 2025
The quarter ended 30 Jun 2024 against the 8 quarters before it.
this quarterearliernormal: 5See the evidence (13 changes)
Short interest and volume: Short interest spike became public on 25 Jul 2024
TScan Therapeutics had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.
This period
1.0M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
83K
How far from its usual level
+5.3
Same report last year
358K
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
TScan Therapeutics had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.
This period
1.2M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
97K
How far from its usual level
+5.5
Same report last year
391K
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
TScan Therapeutics saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.
This period
29 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.0
Same quarter last year
5
History used
1,004 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 27 Aug 2024
TScan Therapeutics had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.
This period
1.3M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
111K
How far from its usual level
+5.3
Same report last year
352K
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
TScan Therapeutics had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.
This period
1.4M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
390K
Typical spread (median absolute deviation)
126K
How far from its usual level
+5.2
Same report last year
335K
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 390K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
TScan Therapeutics had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.
This period
1.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
407K
Typical spread (median absolute deviation)
133K
How far from its usual level
+7.1
Same report last year
377K
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 407K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
TScan Therapeutics had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.
This period
2.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
153K
How far from its usual level
+7.3
Same report last year
567K
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
TScan Therapeutics had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.
This period
2.2M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
161K
How far from its usual level
+7.6
Same report last year
526K
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Nov 2024
TScan Therapeutics had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.
This period
2.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
170K
How far from its usual level
+6.9
Same report last year
471K
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Nov 2024
TScan Therapeutics had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.
This period
2.3M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
182K
How far from its usual level
+6.9
Same report last year
416K
History used
2,513 days
the 15 Nov 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Dec 2024
TScan Therapeutics had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.
This period
2.3M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
451K
Typical spread (median absolute deviation)
220K
How far from its usual level
+5.7
Same report last year
373K
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 451K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2024
TScan Therapeutics had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.
This period
2.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.2
Same report last year
355K
History used
2,541 days
the 13 Dec 2024 report24 earlier reportsnormal: 498K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 14 Jan 2025
TScan Therapeutics had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.
This period
2.5M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
560K
Typical spread (median absolute deviation)
372K
How far from its usual level
+3.5
Same report last year
305K
History used
2,559 days
the 31 Dec 2024 report24 earlier reportsnormal: 560K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.
Same report last year: 305K; its normal report is 560K.
See the evidence
This period
2.5M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
560K
Typical spread (median absolute deviation)
372K
How far from its usual level
+3.5
Same report last year
305K
History used
2,559 days
the 31 Dec 2024 report24 earlier reportsnormal: 560K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.
Same report last year: 355K; its normal report is 498K.
See the evidence
This period
2.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.2
Same report last year
355K
History used
2,541 days
the 13 Dec 2024 report24 earlier reportsnormal: 498K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.
Same report last year: 373K; its normal report is 451K.
See the evidence
This period
2.3M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
451K
Typical spread (median absolute deviation)
220K
How far from its usual level
+5.7
Same report last year
373K
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 451K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.
Same report last year: 416K; its normal report is 418K.
See the evidence
This period
2.3M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
182K
How far from its usual level
+6.9
Same report last year
416K
History used
2,513 days
the 15 Nov 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.
Same report last year: 471K; its normal report is 418K.
See the evidence
This period
2.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
170K
How far from its usual level
+6.9
Same report last year
471K
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.
Same report last year: 526K; its normal report is 418K.
See the evidence
This period
2.2M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
161K
How far from its usual level
+7.6
Same report last year
526K
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.
Same report last year: 567K; its normal report is 418K.
See the evidence
This period
2.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
153K
How far from its usual level
+7.3
Same report last year
567K
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.
Same report last year: 377K; its normal report is 407K.
See the evidence
This period
1.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
407K
Typical spread (median absolute deviation)
133K
How far from its usual level
+7.1
Same report last year
377K
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 407K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.
Same report last year: 335K; its normal report is 390K.
See the evidence
This period
1.4M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
390K
Typical spread (median absolute deviation)
126K
How far from its usual level
+5.2
Same report last year
335K
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 390K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.
Same report last year: 352K; its normal report is 379K.
See the evidence
This period
1.3M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
111K
How far from its usual level
+5.3
Same report last year
352K
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year, while it had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year. Two unrelated kinds of activity within 168 days.
See the evidence (13 changes)
Short interest and volume: Short interest spike became public on 25 Jul 2024
TScan Therapeutics had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.
This period
1.0M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
83K
How far from its usual level
+5.3
Same report last year
358K
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
TScan Therapeutics had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.
This period
1.2M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
97K
How far from its usual level
+5.5
Same report last year
391K
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2024
TScan Therapeutics saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.
This period
29 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.0
Same quarter last year
5
History used
1,004 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 27 Aug 2024
TScan Therapeutics had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.
This period
1.3M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
111K
How far from its usual level
+5.3
Same report last year
352K
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
TScan Therapeutics had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.
This period
1.4M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
390K
Typical spread (median absolute deviation)
126K
How far from its usual level
+5.2
Same report last year
335K
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 390K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
TScan Therapeutics had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.
This period
1.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
407K
Typical spread (median absolute deviation)
133K
How far from its usual level
+7.1
Same report last year
377K
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 407K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
TScan Therapeutics had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.
This period
2.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
153K
How far from its usual level
+7.3
Same report last year
567K
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
TScan Therapeutics had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.
This period
2.2M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
161K
How far from its usual level
+7.6
Same report last year
526K
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Nov 2024
TScan Therapeutics had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.
This period
2.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
170K
How far from its usual level
+6.9
Same report last year
471K
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Nov 2024
TScan Therapeutics had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.
This period
2.3M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
182K
How far from its usual level
+6.9
Same report last year
416K
History used
2,513 days
the 15 Nov 2024 report24 earlier reportsnormal: 418K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Dec 2024
TScan Therapeutics had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.
This period
2.3M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
451K
Typical spread (median absolute deviation)
220K
How far from its usual level
+5.7
Same report last year
373K
History used
2,527 days
the 29 Nov 2024 report24 earlier reportsnormal: 451K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2024
TScan Therapeutics had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.
This period
2.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.2
Same report last year
355K
History used
2,541 days
the 13 Dec 2024 report24 earlier reportsnormal: 498K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 14 Jan 2025
TScan Therapeutics had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.
This period
2.5M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
560K
Typical spread (median absolute deviation)
372K
How far from its usual level
+3.5
Same report last year
305K
History used
2,559 days
the 31 Dec 2024 report24 earlier reportsnormal: 560K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Aug 2024Institutional holdings change
saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.
Same quarter last year: 5; its normal quarter is 5.
See the evidence
This period
29 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.0
Same quarter last year
5
History used
1,004 days
the quarter ended 30 Jun 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.
Same report last year: 391K; its normal report is 379K.
See the evidence
This period
1.2M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
97K
How far from its usual level
+5.5
Same report last year
391K
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.
Same report last year: 358K; its normal report is 375K.
See the evidence
This period
1.0M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
83K
How far from its usual level
+5.3
Same report last year
358K
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.
Not listed: 70 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001783328
Ticker
TCRX
Domain
tscan.com
Employer name
TScan Therapeutics, Inc. (1 unverified)
Hq location
MA|WALTHAM|02451 (1 unverified)
Name
EX-21, tcrx-ex21.htm, TScan Securities Corporation, TScan Therapeutics, Inc.
DOL H-1B labor condition applications and PERM certifications98 data points6 Apr 2020 to 17 Aug 2026
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)99 records26 Jul 2019 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)376 data points31 Dec 2019 to 30 Sep 2026
SEC Form 4 insider transactions24 records, 80 data points22 Jul 2021 to 23 Dec 2025
FINRA short interest (twice monthly)422 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2752 data points1 Aug 2018 to 20 Nov 2026
WARN layoff notices (state labor agencies)1 record, 3 data points31 Aug 2026 to 2 Sep 2026